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A fraction of patients infected with HIV-1 de-
velop broadly neutralizing antibodies against the 
virus (McMichael et al., 2010). In vitro studies   
indicate that these antibodies can reduce infec-
tivity by interfering with virus–target–cell inter-
actions or by blocking viral fusion (Dimmock, 
1993; Robbins et al., 1995; Shibata et al., 1999; 
Zolla-Pazner, 2004). In addition, passive admin-
istration of mABs with broadly neutralizing activ-
ity to macaques or humans can provide sterilizing 
immunity or delay HIV-1 rebound (Emini et al., 
1992;  Gauduin  et  al.,  1995;  Mascola  et  al., 
2000; Trkola et al., 2005). Therefore, it is gen-
erally believed that reproducing this type of   
serologic activity by immunization would be 
important for the development of an effective 
HIV vaccine (Stamatatos et al., 2009).
Although several different broadly neu-
tralizing mABs that target HIV-1 envelope   
epitopes  have  been  described  (Zolla-Pazner, 
2004; Burton et al., 2005), there have been few 
comprehensive efforts to clone and character-
ize the antibodies from patients with broadly   
neutralizing serologic responses. In an effort to 
understand  the  human  antibody  response  to 
HIV-1, we cloned 502 anti-HIV-1 gp140 anti-
bodies from the memory B cell compartment 
of six individuals with variable viral loads and 
high  titers  of  broadly  neutralizing  antibodies 
(Scheid et al., 2009). We found that the mem-
ory B cell response to gp140 is composed of 
high affinity antibodies binding to the gp120 
variable  loops  (VLs),  the  CD4  binding  site 
(CD4bs), the induced coreceptor-binding site 
(CD4is), several different epitopes on gp41   
(Pietzsch et al., 2010), and a group of poten-
tially heterogeneous antibodies to one or more 
epitopes near the CD4bs, termed “core” (Scheid 
et al., 2009). The core antigen was not charac-
terized molecularly; however, antibodies to   
this region accounted for 18% of all anti-gp140   
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The identification and characterization of conserved epitopes on the HIV-1 viral spike that 
are immunogenic in humans and targeted by neutralizing antibodies is an important step in 
vaccine design. Antibody cloning experiments revealed that 32% of all HIV-neutralizing 
antibodies expressed by the memory B cells in patients with high titers of broadly  
neutralizing antibodies recognize one or more “core” epitopes that were not defined. Here, 
we show that anti-core antibodies recognize a single conserved epitope on the gp120 
subunit. Amino acids D474, M475, R476, which are essential for anti-core antibody  
binding, form an immunodominant triad at the outer domain/inner domain junction of 
gp120. The mutation of these residues to alanine impairs viral fusion and fitness. Thus, the 
core epitope, a frequent target of anti–HIV-neutralizing antibodies, including the broadly 
neutralizing antibody HJ16, is conserved and indispensible for viral infectivity. We conclude 
that the core epitope should be considered as a target for vaccine design.
© 2010 Pietzsch et al.  This article is distributed under the terms of an Attribution–
Noncommercial–Share Alike–No Mirror Sites license for the first six months after 
the publication date (see http://www.rupress.org/terms). After six months it is 
available under a Creative Commons License (Attribution–Noncommercial–Share 
Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/
by-nc-sa/3.0/).
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binding of the anti-CD4bs antibody b12 (Pantophlet et al., 
2003) and CD4, respectively (Olshevsky et al., 1990; Fig. 1,   
A and B). These mutations had little or no effect on anti- 
core antibody binding (Fig. 1, A and B). Thus, the binding 
characteristics of the anti-CD4bs and anti-core antibodies are 
distinct. However, as expected from the antibody blocking 
experiments (Corti et al., 2010; Scheid et al., 2009), anti-core 
and anti-CD4bs antibody binding overlapped to a significant 
extent, with varying levels of sensitivity for F376A, P470A, 
W96A, E275A, and D477A (Fig. 1, A and B).
Among the 72 mutants, we found three mutations (D474A, 
M475A, and R476A) that inhibited the binding of anti-core 
antibodies, but had no significant effect on b12 (Fig. 1 C). 
These adjacent residues are in close proximity to the CD4bs 
and cover a stretch from a direct CD4 contact residue (D474) 
up to the 5 helix at the outer-domain/inner-domain junc-
tion of gp120 (M475, R476; Fig. 1 E). Among the 24 anti-
core antibodies, only 2 were insensitive to these 3 mutations. 
Of the remaining 22, 16 were sensitive to both D474A and 
R476A (Fig. 1 D); in addition, 8 of these also showed altered 
binding to M475A (Fig. 1 D).
To determine whether anti-core antibodies recognize a 
linear peptide epitope containing D474, M475, and R476   
we  performed  ELISAs  with  the  DTNGTEIFRPGGG 
DMRDNWR peptide. Controls included a V3-loop peptide 
(NNNTRKSINIGPGRALYTT) that was recognized by an 
anti-V3-loop antibody (2–59; Scheid et al., 2009). We found 
that none of the 24 anti-core antibodies recognized this pep-
tide (Fig. S2). Thus, anti-core antibodies recognize a confor-
mational epitope containing amino acids D474, M475, and 
R476 in gp120 (Fig. 1, A–E).
Antibodies from EBV-transformed B cells
mABs with properties similar to anti-core that were able to com-
pletely or partially block the binding of sCD4 to Env-coated 
ELISA plates, henceforth defined as CD4bs- or partial CD4bs–
specific mAbs were recently obtained from EBV immortalized 
memory B cells (Corti et al., 2010). To determine whether these   
antibodies (HGF12, HGI46, HGS2, HGW26, HGZ1, and 
HJ16) show binding characteristics similar to anti-core anti-
bodies, we assayed all anti–partial CD4bs antibodies for binding 
to core epitope alanine mutants by ELISA (Fig. S3). Two of the 
antibodies (HGF12 and HGI46) could not be mapped; two   
others (HGW26 and HGZ1) were sensitive to D368A/E370A 
mutation and are likely to be conventional anti-CD4bs anti-
bodies. HGS2 and HJ16 were sensitive to D474A, R476A, and 
M475A/R476A, but not to D368A; therefore, they target the 
same epitope as anti-core antibodies. Among these antibodies, 
HJ16 is of special interest because it is a broad and potent HIV 
neutralizer with very peculiar features, such a preferential neu-
tralization of isolates not neutralized by b12 and an almost exclu-
sive capacity to neutralize tier 2 isolates (Corti et al., 2010).
Trimeric BaL gp140
To confirm the mapping studies on trimeric gp140 of a   
different HIV strain, we produced BaL gp140 trimer and   
antibodies and 32% of all antibodies with neutralizing activity 
(Table S1; Scheid et al., 2009). Anti-core was the largest sin-
gle group of neutralizers in the six patients studied. In addi-
tion,  antibodies  with  characteristics  similar  to  anti-core 
antibodies were also reported in a collection of mABs ob-
tained from EBV-transformed B cells (“partial CD4 binding 
site” antibodies; Corti et al., 2010).
Anti-core antibodies bind to gp120, gp120core (a mutant 
that lacks V1-V3; Kwong et al., 1998), gp120D368R (which 
interferes with binding by CD4 and anti-CD4bs antibodies; 
Olshevsky et al., 1990; Thali et al., 1991; Pantophlet et al., 
2003; Li et al., 2007), and gp120I420R (a mutant that interferes 
with the binding of anti-CD4–induced site [CD4is] anti-
bodies; Thali et al., 1993). Anti-core antibodies do not bind 
to a stabilized gp120core protein that retains CD4 and b12 
binding sites, but is mutated to reduce the flexibility of gp120 
to improve presentation of conserved but discontinuous epi-
topes (Zhou et al., 2007; Scheid et al., 2009). Furthermore, 
anti-CD4bs and some anti-CD4is antibodies inhibit the bind-
ing of anti-core antibodies, suggesting that anti-core antibodies 
recognize an epitope that is closer to the CD4bs than to the 
CD4is (Scheid et al., 2009).
Here, we report on the characteristics of this new epit-
ope. The data show that anti-core antibodies target a confor-
mational epitope on gp120 found within the 5-helix of the 
molecule, which is highly conserved across different HIV-1 
clades. This high degree of conservation correlates to viral 
fitness, as mutating the epitope results in loss of infectivity.
RESULTS
Fine mapping of anti-core antibodies cloned  
by single cell sorting
To map the epitope or epitopes recognized by anti-core an-
tibodies, we assayed all anti-core antibodies for binding to 72 
different alanine mutants of HIV-1 gp120 by ELISA. Con-
trols included the anti-CD4bs antibody b12 (Burton et al., 
1994; Saphire et al., 2001) and an anti–variable-loop anti-
body (1–79; Scheid et al., 2009). Mutations that reduced anti-
body binding to 60% or less compared with the WT protein 
were considered significant. The mutated residues were pri-
marily spread across gp120 to cover a broad range of candi-
date binding sites, and then refined based on initial binding 
results. In particular, we included residues from the variable-
loop 2 (VL2), the silent face, the CD4bs, the CD4is, the Phe 
43-cavity (Kwong et al., 1998), in addition to residues that lie 
proximal or distal to these sites (Fig. 1 A and Fig. S1).
We  found  nine  mutations  that  altered  the  binding  of 
nearly all anti-core antibodies and b12, despite being physi-
cally distant from the CD4bs recognized by b12. Based on 
their position and physical chemical characteristics, these resi-
dues (L288, I449, T450, L265A, S264, C378, N262, F383, 
and F376) appear to be required to maintain the structural 
integrity of the molecule.
As previously demonstrated, alanine substitutions in the   
CD4bs (E370A, D368A, and D368A/E370A), or in close   
proximity to the CD4bs (N276A, R480A, and Y384A) reduce JEM VOL. 207, August 30, 2010 
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Binding to cell surface BaL gp160c trimer
The gp120 monomer and the artificial gp140 
trimer lack yet to be defined features found on 
cell surface expressed gp160 viral spikes. To ex-
amine anti-core antibody binding to membrane- 
anchored molecules, we measured binding to   
a native gp160 trimer lacking the cytoplasmic 
domain of the spike (gp160c) expressed on 
the surface of BOSC.23 cells. Anti-core anti-
bodies  (4–79  and  HGS2)  bind  the  gp160c   
trimer,  but  not  the  mutant  trimer  (BaL 
gp160cD474A/M475A/R476A). In contrast, b12 and 
the anti-VL antibodies bound to both gp160c 
and the gp160c mutant membrane anchored 
proteins. We conclude that the core epitope is 
accessible on the functional and fusion compe-
tent (see below) form of the HIV-1 spike and that 
it differs from the epitope recognized by the b12 
anti-CD4bs antibody (Fig. 2 C).
Core epitope conservation
Given that most anti-core antibodies from different patients 
recognize a common epitope, we explored the possibility 
that D474, M475, and R476 might be conserved across dif-
ferent HIV-1 strains. Among 1,963 sequences analyzed from 
all clades (QuickAlign; http://www.hiv.lanl.gov), 56% con-
tained all three of these residues and 35% of the remaining 
showed strong homology. Thus, the core epitope shows a 
moderate degree of precise conservation based on the pri-
mary amino acid sequence, but is highly conserved if homol-
ogy is considered (Table S3).
Fusion and infectivity
To elucidate the possible roles of D474, M475, and R476 in 
fusion we developed an assay to measure fusion between 
BOSC.23 cells coexpressing BaL gp160c trimer and GFP, 
corresponding core epitope mutant (BaL gp140D474A/M475A/R476A)   
and repeated the ELISAs with two randomly selected anti-core 
antibodies (4–79 and HGS2), b12, and anti-VL controls. All of 
the antibodies tested showed similar binding characteristics on 
gp120 and the gp140 trimers (Fig. 2 A and Fig. S4).
To obtain a more precise measurement of the affinities   
of the antibodies to WT and mutant trimeric gp140 we per-
formed surface plasmon resonance (SPR) experiments. The 
two anti-core antibodies, 4–79 and HGS2, bound to WT 
gp140 with high affinity KAs of 3.8 × 109 and 1.4 × 1010, re-
spectively, but binding to the mutant gp140D474A/M475A/R476A 
could not be detected. In contrast, control antibodies target-
ing the VL (2–1092) and the CD4bs (b12) retained their 
high-affinity binding to gp140D474A/M475A/R476A, with KAs 
ranging from 9.6 × 108 to 4.8 × 109 (Fig. 2 B, Fig. S5, and   
Table S2).
Figure 1.  Mapping of the HIV-1 gp120 core  
epitope. (A) Heat map summarizes the binding of the 
different anti-core antibodies and b12 to gp120 alanine 
mutants. Red and orange fields indicate <60% binding, 
whereas yellow shows no difference compared with the 
WT gp120 control. The mapping of the anti-core epitope 
has been confirmed by three independent experiments. 
(B) Surface diagram of gp120 (PDB ID: 3DNO; Liu et al., 
2008) showing the CD4bs (blue), the CD4is (gray), the 
b12 binding sites (yellow), and the core epitope (green). 
Residues that distinguished between the anti-CD4bs 
epitope and anti-core epitope are highlighted with  
circles. (C) Diagram shows the apparent binding of anti-
core antibodies and b12 to mutant gp120D474AM475AR476A 
relative to gp120 WT in percent. The red star indicates 
binding to D368A. (D) Venn diagram summarizes the 
sensitivity for anti-core antibodies binding to D474A, 
M475A, and R476A. (E) Ribbon diagram of gp120 (PDB ID:  
3DNO; Liu et al., 2008) shows the CD4bs (blue), the CD4is 
(gray), and the core epitope (green).1998 Characterization of the HIV-1 “core” epitope | Pietzsch et al.
To investigate the role of D474, M475, and R476 in viral 
infectivity, we assayed for the infection of TZM.bl cells with 
HIV-1 YU-2 and BaL pseudo-virus mutants (Fig. 3 C). YU-2 
gp160D474A/M475A/R476A pseudo viruses showed a decrease in 
infectivity of four orders of magnitude at constant p24 levels 
(Table S4). The BaL pseudo virus was more sensitive to the 
mutation of the core epitope. R476A and M475A/R476A 
mutants decreased infectivity by two and three orders of magni-
tude, respectively, and we could not detect infection with the 
D474A mutant.
Collectively, the data from cell fusion and pseudo-virus 
infection experiments indicate that residues D474, M475, and   
R476 are important for optimal viral infectivity.
DISCUSSION
Although strong evidence suggests that any antibody that can 
bind to the HIV spike will neutralize the virus, only a small 
number of epitopes that induced broadly neutralizing anti-
bodies upon HIV infection have been defined. These include 
the 1→2 mannose residues recognized by 2G12 (Trkola   
et al., 1996; Scanlan et al., 2002), the central region of the 
CD4bs bound by b12 (Barbas et al., 1992), and the V1/V2 
with  TZM.bl  cells  expressing  red  fluorescent  protein 
(mCherry). Fusion between TZM.bl and BOSC.23 cells ex-
pressing the gp160c trimer, but not empty control GFP+ 
BOSC.23 cells, was readily detected by flow cytometry   
(Fig. 3 A). In contrast, there was little if any fusion of cells ex-
pressing the mutant spike (BaL gp160cD474A/M475A/R476A).
To confirm that the events detected by flow cytometry 
represent fusion as opposed to binding, we repeated the ex-
periments and analyzed them by image-based flow cytometry 
(ImageStream100; Amnis). Fusion was the predominant event 
when BOSC.23 cells expressed the gp160c trimer (Fig. 3 B). 
We conclude that D474, M475, and R476 are required for 
optimal fusion.
Figure 2.  Binding to soluble and cell surface trimeric gp160c.  
(A) Graphs show optical density at 405 nm (OD405nm) for the selected IgG 
antibodies as measured by capture ELISA with purified BaL gp140 WT and 
BaL gp140D474A/M475A/R476A. See also Fig. S4. Error bars represent the SD 
from at least two independent experiments. (B) Graphs show apparent KA 
(KA
app, M21) for the selected IgG antibodies as measured by surface plas-
mon resonance (SPR) on chips derivatized with BaL gp140 WT and  
BaLD474A/M475AR/476A. See also Fig. S5 and Table S2. Error bars represent the 
SEM from at least two independent experiments. * indicates that no binding 
to BaL gp140D474A/M475A/R476A was detected. (C) (left) Histogram plots  
show the binding of the selected antibodies to BaL gp160c and BaL  
gp160cD474A/M475A/R476A expressed on GFP-positive BOSC.23 cells. Controls 
include mgo53 (Wardemann et al., 2003), mAbs 2–1092 (anti-VL) and b12 
(anti-CD4bs). BOSC.23 cells gated on GFPhigh expression. The number of 
binding events as percentage of the maximum was plotted against APC 
fluorescence intensity. (right) Graphs show apparent differences in the 
relative median fluorescence intensity (rMFI) for the selected IgG anti-
bodies between BaL gp160c and BaL gp160cD474A/M475A/R476A. Error  
bars represent the SD from at least two independent experiments.
Figure 3.  Fusion and infectivity. (A) (left) Histogram plots summarize 
fusion between BOSC.23 cells expressing GFP alone (w/o) or BaL gp160c 
or BaL gp160cD474A/M475A/R476A with mCherry expressing TZM.bl cells. 
(right) Fusion events (%) with mean and standard deviation for at least 
two independent experiments. (B) Image-based analysis of fusion. (left) 
Single staining compensation controls for BOSC.23 cells expressing BaL 
gp160c and GFP, mCherry expressing TZM.bl cells and CD4-APC stained 
TZM.bl cells. (middle) An intermediate fusion event. (right) The colocaliza-
tion of the GFP-mCherry-APC signal after fusion. Experiment has been 
performed twice. (C) Graphs show the titration curves for TZM.bl cell in-
fection by YU2 and BaL pseudoviruses, which has been performed twice. 
RLU relative light unit.JEM VOL. 207, August 30, 2010 
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suggest that this group of antibodies should be referred to 
anti-CD4bs/DMR. Although this group of antibodies recog-
nizes the same epitope, they are heterogeneous with respect to 
their neutralizing breadth and potency (Scheid et al., 2009; 
Corti et al., 2010). Similarly, traditional anti-CD4bs antibodies 
sensitive to the D368R mutation also show a wide range of 
neutralizing activity (Chen et al., 2009; Scheid et al., 2009; 
Corti et al., 2010). The structural basis for the difference is 
not entirely clear for either of the two classes of antibodies 
despite extensive structural information on the more tradi-
tional CD4bs antibodies. For example, there were only subtle 
differences between the structures of CD4bs antibodies F105 
and b12 bound to a fragment of gp120, despite enormous 
differences in neutralizing activity (Chen et al., 2009). Further 
understanding of the molecular basis of differences in the 
neutralizing activity of these antibodies may require deter-
mining the structure of their cocrystals with native gp160.
Anti-CD4bs/DMR antibodies recognize a conforma-
tional epitope that includes the 5 helix at the outer-domain–
inner-domain junction of gp120. The core epitope is highly 
conserved across different HIV-1 isolates and is essential for 
optimal  infectivity,  and  therefore  for  viral  fitness.  Impor-
tantly,  anti-CD4bs/DMR  antibodies  resemble  b3  and  b6   
antibodies that were isolated as Fab fragments from a phage 
display library and lack neutralizing activity (Burton et al., 
1991; Barbas et al., 1992; Pantophlet et al., 2003). Based on 
the comparative analysis of the structure of b12, which is 
broadly neutralizing, and b6, which is not, it has been sug-
gested that a stabilized core protein, which does not allow b6 
(Pantophlet et al., 2003; Zhou et al., 2007) or anti-core anti-
body (Scheid et al., 2009) binding, should be used as a vaccine 
immunogen (Dey et al., 2007, 2009; Mörner et al., 2009). 
However, antibodies to the core epitope can account for a 
significant fraction of the neutralizing activity in sera (Li et al., 
2007), and of the antibodies produced by memory B cells 
(Scheid et al., 2009; Corti et al., 2010), including potent and 
broadly neutralizing antibodies (Corti et al., 2010). There-
fore, we would like to suggest that an optimal HIV vaccine 
immunogen may require inclusion of the core epitope.
MATERIAL AND METHODS
mABs. Anti-human HIV-1 gp140 antibodies were described in (Barbas   
et al., 1992; Wardemann et al., 2003; Tiller et al., 2008; Scheid et al., 2009; 
Corti et al., 2010). All IgGs were expressed by cotransfection in HEK-293T 
cells (American Type Culture Collection). All work with human samples 
was performed in accordance with approved Institutional Review Board 
protocols (Scheid et al., 2009).
Mutagenesis and expression of recombinant gp120. Amino acid num-
bering refers to the HXB2CG reference sequence (Korber et al., 1998). Alanine 
mutations were introduced into pYU2gp120 (obtained from J. Sodroski, 
Dana-Farber Cancer Institute, Harvard School of Public Health, Boston, MA) 
using the QuickChange Lightning Site-Directed Mutagenesis kit (Stratagene) 
according to the manufacturer’s instructions. Mutagenesis primers were designed 
using Stratagene’s web-based QuickChange primer design program. All site-
directed mutations generated in this study were verified by DNA sequencing.
Recombinant proteins were produced in HEK-293T cells (American 
Type Culture Collection) grown in Dulbecco’s modified Eagle’s medium 
and V3 loops recognized by PG9 and PG16 (Walker et al., 
2009; Walker and Burton, 2010). Unfortunately, vaccination 
approaches using recombinant HIV envelope proteins and 
derivatives specifically engineered to elicit broadly neutraliz-
ing antibodies have all been disappointing to date. Thus, the 
identification of additional immunogenic targets of neutralizing 
antibodies on the HIV viral spike remains an important issue in 
HIV vaccine research (Mascola and Montefiori, 2010). Optimal 
vaccine epitopes should be immunogenic in humans, conserved 
among HIV isolates and required for optimal viral infectivity. 
The core epitope fits all of these criteria.
Anti-core antibodies represent 18% of all anti-gp140 anti-
bodies cloned from the memory B cell compartment of pa-
tients with high titers of broadly neutralizing antibodies (Scheid 
et al., 2009), but most importantly, they represent the most fre-
quent neutralizers, accounting for 32% of all HIV-1 neutral-
izing antibodies (Scheid et al., 2009). In contrast, 18% of the 
neutralizing antibodies cloned in the same study showed bind-
ing properties similar to the anti-CD4bs antibody b12, 27% 
were anti-VL directed, and 23% recognized the CD4is (Scheid 
et al., 2009).
Neutralizing antibodies targeting a region other than the 
“central region of the CD4bs” were found in the sera of pa-
tients with broadly neutralizing serologic activity (Li et al., 
2007). Anti-core plus anti-CD4bs containing serum and IgG 
fraction  eluted  from  gp120core  (which  lacks  VL  1–3,  and 
therefore the CD4is) was more potent in viral neutralization 
than the anti–CD4bs-antibody–enriched fraction alone (Li   
et al., 2007). Thus, the serologic data are in agreement with the 
antibody-cloning experiments; both indicate that anti-core 
antibodies contribute significantly to the overall neutralizing   
activity in human serum.
Most antibodies that bind to HIV neutralizing epitopes 
are restricted in their neutralizing activity, including antibodies 
to the CD4bs. For example, among the antibodies that are 
like b12 and sensitive to the D368A mutation, most show 
neutralizing activity against tier 1 viruses, but much more 
limited activity against tier 2 viruses (Wyatt and Sodroski, 
1998; Mascola, 2003; Pantophlet and Burton, 2006; Karlsson 
Hedestam et al., 2008; Scheid et al., 2009; Stamatatos et al., 
2009). Similarly, most anti-core antibodies are not broad but 
are instead restricted to neutralize one or another strain of   
HIV-1. However, like the traditional anti-CD4bs antibodies, an   
occasional  anti-core  antibody,  HJ16  exhibits  a  breadth  of 
neutralizing activity comparable to, and generally comple-
mentary to b12, being able to neutralize approximately one 
third of all HIV-1 isolates tested, irrespective of clade (Corti   
et al., 2010). HJ16 also showed selective neutralization of tier 2, 
and not tier 1, isolates, making it particularly interesting as a 
template for vaccine design (Corti et al., 2010). Moreover, 
HJ16 was obtained from a clade C–infected patient, whereas 
the antibodies we cloned were obtained from clade B in-
fected patients; therefore, the core epitope is immunogenic in 
humans even across different HIV isolates and clades.
Anti-core  antibodies  recognize  a  common  epitope  in 
close proximity to the CD4bs. We would therefore like to 2000 Characterization of the HIV-1 “core” epitope | Pietzsch et al.
and binding constants (KA1[M], KA2[RU21]) were calculated after subtrac-
tion of backgrounds (binding to a control flow cell and signal of the HBS-
EP+  running  buffer)  using  Biacore  T100  Evaluation  software  using  the 
kinetic analysis and the bivalent model. KA1 value was used as an estimation 
of apparent KA (KA
app) because KA1 represents the majority of the binding.
Expression of the native gp160c trimer and FACS-based binding 
assay.  Codon-optimized  human  BaL  gp160  plasmid  (pSF219;  obtained 
from A.L. DeVico, University of Maryland, Baltimore, MD), whose intra-
cellular tail was deleted (gp160c), was subcloned into pMX-IRES-GFP 
(Robbiani et al., 2008). Alanine mutations (D474A/M475A/R476A) were 
introduced as described in the previous paragraph and confirmed by sequenc-
ing. Human embryonic kidney BOSC.23 cells (American Type Culture 
Collection) were maintained in Dulbecco’s modified Eagle’s medium (Invitro-
gen) supplemented with 10% (vol/vol) fetal calf serum, 1% (vol/vol) antibiotic-
antimycotic  (Invitrogen),  and  1%  (vol/vol)  l-glutamine  (Invitrogen). 
FuGENE 6 (Roche) was used for transient transfection according to the man-
ufacturer’s instructions. 24 h later, cells were harvested with enzyme-free cell 
dissociation  buffer  (Invitrogen)  and  stained  with  dialyzed  human  mABs   
(2–1092, 4–79, HGS2, mgo53, and b12) at 0.4 µg/ml for 30 min at 4°C. Pri-
mary antibodies were visualized with APC-conjugated mouse anti–human IgG 
antibody (BD) according to the manufacturer’s instructions. Flow cytometry 
was perfomed on FACSCalibur (BD). The median fluorescence intensity 
(MFI) was calculated using FlowJo software. The differences in relative MFI 
(rMFI) between gp160c and MUT BaL gp160c were calculated accord-
ing the following formula: rMFI = 100 × (1 2 [{MFI – MFIMUT}/MFI]).
Fusion assay. BaL gp160c and gp160c D474A/M475A/R476A were 
expressed on BOSC.23 cells, harvested as described, and mixed with mCherry 
positive  TZM.bl  cells  in  excess.  The  cell  suspension  was  centrifuged  at   
657× g and 37°C for 1 h and incubated for one additional hour at 37°C and 
5% CO2, then treated with 0.05% Trypsin-EDTA. Cells were assayed on 
ImageStream100 (Amnis) and BD LSR II (BD Biosciences) and analyzed with 
FlowJo software. Fused cells (%) = n(GFP+mCherry+)/ [n(GFP+mCherry+) + 
n(GFP+mCherry-)].
HIV-1 pseudovirus infectivity assay. Alanine mutations were intro-
duced in pYU-2Env and pBaL-Env as described above. Clones were   
cotransfected with pHIVEnv in HEK-293 T cells. The virus stocks were 
titrated on TZM.bl cells to measure the median tissue culture infective dose 
(TCID50; Li et al., 2005). p24 ELISAs (ZeptoMetrix) were performed   
according to manufacturer’s instructions.
Online supplemental material. The supplemental material includes re-
sults of the mapping ELISA (Figs. S1, 3, and 4), the peptide ELISA (Fig. S2), 
SPR sensograms (Fig. S5), TZM.bl neutralization assay (Table S1), SPR   
affinities (Table S2), conservation of the core epitope (Table S3), and the 
pseudo virus infectivity assay (Table S4). Online supplemental material is 
available at http://www.jem.org/cgi/content/full/jem.20101176/DC1.
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(Invitrogen) supplemented with 1% (vol/vol) antibiotic-antimycotic (Invitro-
gen), 1% (vol/vol) l-glutamine (Invitrogen), and 1% (vol/vol) nutridoma-sp 
(Roche) that were transiently transfected with WT or mutant pYU2gp120 
plasmids (50 µg). 3 d after transfection, culture supernatants were harvested 
and stored at 4°C and supplemented with complete protease inhibitor cock-
tail tablets (Roche) until use in ELISA.
ELISAs. To determine concentrations of the expressed gp120 proteins, 
ELISA plates (high-binding capacity; Corning) were coated with affinity-
purified sheep anti–HIV-1gp120 antibody (Aalto Bio Reagents) recognizing 
a linear peptide at the carboxy-terminus (497–511; APTKAKRRVVQREKR) 
in PBS overnight at 5 µg/ml. The gp120 mutants were captured and detected 
with an anti-VL antibody (1–79; Scheid et al., 2009). The protein concen-
tration of the gp120 mutants was determined using a gp120 standard and ad-
justed to 20 µg/ml.
To determine the relative binding of anti-core antibodies to the differ-
ent gp120 mutants (MUT) compared with gp120WT, ELISA plates were 
coated as described in the previous paragraph. After washing with ultra pure 
water and blocking with 2 mM EDTA and 0.05% Tween-20 in PBS for   
30 min at room temperature, mutant proteins were captured at 20 µg/ml for 
2 h. Anti-core antibodies were incubated with the washed plates at serial di-
lutions in PBS-10% sheep serum (Equitech-Bio). Bound antibodies were 
detected with peroxidase conjugated affinity purified goat anti-Human IgG 
(Jackson ImmunoResearch Laboratories) using an HRP substrate kit (Bio-
Rad Laboratories). The ELISA graphs were used to determine the linear 
range of antibody binding. The optical density (OD405nm) for binding of a 
given antibody to gp120MUT divided by the OD405nm of the same antibody 
to gp120WT was considered the percentage of apparent binding.
Peptide ELISA. Peptide ELISAs were performed as previously described 
(Mouquet et al., 2006). In brief, ELISA plates (Corning) were coated with 
50 µl of a peptide containing the core epitope (underlined; DTNGTEIFRP-
GGGDMRDNWR) at 5 µg/ml, in PBS over night at room temperature. 
After washing three times with PBS-0.1% Tween 20 (PBST), wells were 
blocked with 1% PBS, 5% Tween20, and 3% sucrose milk powder for 1 h at 
room temperature. Serial dilutions of anti-core antibodies (starting at 4 µg/ml 
in PBST-1% BSA) were added, incubated for 1 h at room temperature, and 
visualized with peroxidase-conjugated affinity purified goat anti–human IgG 
(Jackson ImmunoResearch Laboratories) using an HRP substrate kit (Bio-
Rad Laboratories). Controls included a V3-loop peptide (NNNTRKSIN-
IGPGRALYTT) that was recognized by an anti-V3-loop antibody (2–59).
Mutagenesis and expression of recombinant gp140. Codon-optimized 
human BaL gp160 plasmid (pSF219; obtained from A.L. DeVico, University 
of Maryland, Baltimore, MD) was subcloned into pCDNA3.1. Mutations at 
the proteolytic cleavage site were introduced (arginines 508 and 511 to 
serines), as well as the trimerization domain from the C terminus of bacte-
riophage T4 fibritin inserted, thus leading to pBaLgp140683(-/FT) (Yang 
et al., 2002). Alanine mutations (D474A/M475A/R476A) were introduced 
as described and confirmed by sequencing. Recombinant proteins were pro-
duced in HEK-293T cells as described and purified by lectin and nickel-
chelate affinity chromatography (Freeze, 2001; Petty, 1996).
Surface  plasmon  resonance.  All  experiments  were  performed  with  a   
Biacore T100 (Biacore, Inc.) in HBS-EP+ running buffer (Biacore, Inc.) at 
25°C. Samples were analyzed in kinetic experiments performed at least in 
duplicate. BaL gp140 WT and DMR/AAA mutant proteins at 62.5 µg/ml 
were immobilized on CM5 chips (Biacore, Inc.) by amine coupling at pH 4.5, 
resulting in an immobilization level of 5,000 RUs. For kinetic measurements 
on the gp140 WT- and gp140 DMR/AAA-derivatized chips, IgGs were in-
jected through flow cells at 333 nM and 4 successive 1:2 dilutions in HBS-EP+ 
running buffer (Biacore, Inc.) at flow rates of 40 µl/min with 3-min associa-
tion and 5-min dissociation. The sensor surface was regenerated between 
each experiment with a 30-s injection of 10 mM glycine-HCl, pH 2.5, at a 
flow rate of 50 µl/min. Off rate (s21), on rate (ka1[M21s21, ka1[RU21s21]), JEM VOL. 207, August 30, 2010 
Article
2001
Li, Y., S.A. Migueles, B. Welcher, K. Svehla, A. Phogat, M.K. Louder, X. 
Wu, G.M. Shaw, M. Connors, R.T. Wyatt, and J.R. Mascola. 2007. 
Broad HIV-1 neutralization mediated by CD4-binding site antibodies. 
Nat. Med. 13:1032–1034. doi:10.1038/nm1624
Liu,  J.,  A.  Bartesaghi,  M.J.  Borgnia,  G.  Sapiro,  and  S.  Subramaniam.   
2008. Molecular architecture of native HIV-1 gp120 trimers. Nature. 
455:109–113. doi:10.1038/nature07159
Mascola, J.R. 2003. Defining the protective antibody response for HIV-1. 
Curr. Mol. Med. 3:209–216. doi:10.2174/1566524033479799
Mascola, J.R., and D.C. Montefiori. 2010. The role of antibodies in HIV 
vaccines. Annu. Rev. Immunol. 28:413–444. doi:10.1146/annurev- 
immunol-030409-101256
Mascola, J.R., G. Stiegler, T.C. VanCott, H. Katinger, C.B. Carpenter, 
C.E. Hanson, H. Beary, D. Hayes, S.S. Frankel, D.L. Birx, and M.G. 
Lewis. 2000. Protection of macaques against vaginal transmission of a 
pathogenic HIV-1/SIV chimeric virus by passive infusion of neutral-
izing antibodies. Nat. Med. 6:207–210. doi:10.1038/72318
McMichael, A.J., P. Borrow, G.D. Tomaras, N. Goonetilleke, and B.F. 
Haynes. 2010. The immune response during acute HIV-1 infection: clues   
for vaccine development. Nat. Rev. Immunol. 10:11–23. doi:10.1038/nri2674
Mörner, A., I. Douagi, M.N. Forsell, C. Sundling, P. Dosenovic, S. O’Dell, 
B. Dey, P.D. Kwong, G. Voss, R. Thorstensson, et al. 2009. Human 
immunodeficiency virus type 1 env trimer immunization of macaques 
and  impact  of  priming  with  viral  vector  or  stabilized  core  protein.  
J. Virol. 83:540–551. doi:10.1128/JVI.01102-08
Mouquet, H., S. Farci, P. Joly, B. Maillère, J. Leblond, L. Drouot, J. Leprince, 
M.C. Tonon, P. Loiseau, D. Charron, F. Tron, D. Gilbert. 2006. A 
truncated alternative spliced isoform of human desmoglein 1 contains 
a specific T cell epitope binding to the pemphigus foliaceus-associated 
HLA class II DRbeta1*0102 molecule. J. Immunol. 177:6517–6526.
Olshevsky, U., E. Helseth, C. Furman, J. Li, W. Haseltine, and J. Sodroski. 
1990. Identification of individual human immunodeficiency virus type 1   
gp120 amino acids important for CD4 receptor binding. J. Virol. 64: 
5701–5707.
Pantophlet, R., and D.R. Burton. 2006. GP120: target for neutralizing 
HIV-1  antibodies.  Annu.  Rev.  Immunol.  24:739–769.  doi:10.1146/ 
annurev.immunol.24.021605.090557
Pantophlet, R., E. Ollmann Saphire, P. Poignard, P.W. Parren, I.A. Wilson, 
and D.R. Burton. 2003. Fine mapping of the interaction of neutralizing 
and nonneutralizing monoclonal antibodies with the CD4 binding site 
of human immunodeficiency virus type 1 gp120. J. Virol. 77:642–658. 
doi:10.1128/JVI.77.1.642-658.2003
Petty,  K.J.  1996.  Metal-Chelate  Affinity  Chromatography.  Curr.  Protoc. 
Protein Sci. Chapter 9: Unit 9.4.
Pietzsch, J., J.F. Scheid, H. Mouquet, M.S. Seaman, C.C. Broder, and M.C. 
Nussenzweig. 2010. Anti-gp41 antibodies cloned from HIV-infected 
patients with broadly neutralizing serologic activity. J. Virol. 84:5032–
5042. doi:10.1128/JVI.00154-10
Robbiani, D.F., A. Bothmer, E. Callen, B. Reina-San-Martin, Y. Dorsett, 
S.  Difilippantonio,  D.J.  Bolland,  H.T.  Chen,  A.E.  Corcoran,  A. 
Nussenzweig, and M.C. Nussenzweig. 2008. AID is required for the 
chromosomal breaks in c-myc that lead to c-myc/IgH translocations. 
Cell. 135:1028–1038. doi:10.1016/j.cell.2008.09.062
Robbins, J.B., R. Schneerson, and S.C. Szu. 1995. Perspective: hypothesis: 
serum IgG antibody is sufficient to confer protection against infectious 
diseases by inactivating the inoculum. J. Infect. Dis. 171:1387–1398.
Saphire, E.O., P.W. Parren, R. Pantophlet, M.B. Zwick, G.M. Morris, P.M. 
Rudd, R.A. Dwek, R.L. Stanfield, D.R. Burton, and I.A. Wilson. 2001. 
Crystal structure of a neutralizing human IGG against HIV-1: a template   
for vaccine design. Science. 293:1155–1159. doi:10.1126/science.1061692
Scanlan, C.N., R. Pantophlet, M.R. Wormald, E. Ollmann Saphire, R. 
Stanfield, I.A. Wilson, H. Katinger, R.A. Dwek, P.M. Rudd, and D.R.  
Burton. 2002. The broadly neutralizing anti-human immunodeficiency   
virus type 1 antibody 2G12 recognizes a cluster of alpha1—>2 mannose   
residues on the outer face of gp120. J. Virol. 76:7306–7321. doi:10.1128/ 
JVI.76.14.7306-7321.2002
Scheid,  J.F.,  H.  Mouquet,  N.  Feldhahn,  M.S.  Seaman,  K.  Velinzon, 
J.  Pietzsch,  R.G.  Ott,  R.M.  Anthony,  H.  Zebroski,  A.  Hurley,   
et  al.  2009.  Broad  diversity  of  neutralizing  antibodies  isolated  from 
REFERENCES
Barbas, C.F. III, E. Björling, F. Chiodi, N. Dunlop, D. Cababa, T.M. 
Jones,  S.L.  Zebedee,  M.A.  Persson,  P.L.  Nara,  E.  Norrby,  et  al. 
1992. Recombinant human Fab fragments neutralize human type 1   
immunodeficiency  virus  in  vitro.  Proc.  Natl.  Acad.  Sci.  USA.  89: 
9339–9343. doi:10.1073/pnas.89.19.9339
Burton, D.R., C.F. Barbas III, M.A. Persson, S. Koenig, R.M. Chanock, 
and R.A. Lerner. 1991. A large array of human monoclonal antibodies 
to type 1 human immunodeficiency virus from combinatorial libraries 
of asymptomatic seropositive individuals. Proc. Natl. Acad. Sci. USA. 88: 
10134–10137. doi:10.1073/pnas.88.22.10134
Burton, D.R., J. Pyati, R. Koduri, S.J. Sharp, G.B. Thornton, P.W. Parren, 
L.S. Sawyer, R.M. Hendry, N. Dunlop, P.L. Nara, et al. 1994. Efficient 
neutralization of primary isolates of HIV-1 by a recombinant human 
monoclonal antibody. Science. 266:1024–1027. doi:10.1126/science 
.7973652
Burton, D.R., R.L. Stanfield, and I.A. Wilson. 2005. Antibody vs. HIV in a   
clash of evolutionary titans. Proc. Natl. Acad. Sci. USA. 102:14943–14948. 
doi:10.1073/pnas.0505126102
Chen, L., Y.D. Kwon, T. Zhou, X. Wu, S. O’Dell, L. Cavacini, A.J. 
Hessell, M. Pancera, M. Tang, L. Xu, et al. 2009. Structural basis of im-
mune evasion at the site of CD4 attachment on HIV-1 gp120. Science. 
326:1123–1127. doi:10.1126/science.1175868
Corti,  D.,  J.P.  Langedijk,  A.  Hinz,  M.S.  Seaman,  F.  Vanzetta,  B.M. 
Fernandez-Rodriguez,  C.  Silacci,  D.  Pinna,  D.  Jarrossay,  S.  Balla-
Jhagjhoorsingh, et al. 2010. Analysis of memory B cell responses and 
isolation of novel monoclonal antibodies with neutralizing breadth from 
HIV-1-infected individuals. PLoS One. 5:e8805. doi:10.1371/journal 
.pone.0008805
Dey, B., M. Pancera, K. Svehla, Y. Shu, S.H. Xiang, J. Vainshtein, Y. 
Li,  J.  Sodroski,  P.D.  Kwong,  J.R.  Mascola,  and  R.  Wyatt.  2007. 
Characterization of human immunodeficiency virus type 1 monomeric   
and trimeric gp120 glycoproteins stabilized in the CD4-bound state:   
antigenicity, biophysics, and immunogenicity. J. Virol. 81:5579–5593. 
doi:10.1128/JVI.02500-06
Dey, B., K. Svehla, L. Xu, D. Wycuff, T. Zhou, G. Voss, A. Phogat, B.K. 
Chakrabarti, Y. Li, G. Shaw, et al. 2009. Structure-based stabilization 
of HIV-1 gp120 enhances humoral immune responses to the induced 
co-receptor binding site. PLoS Pathog. 5:e1000445. doi:10.1371/journal 
.ppat.1000445
Dimmock, N.J. 1993. Neutralization of animal viruses. Curr. Top. Microbiol. 
Immunol. 183:1–149.
Emini, E.A., W.A. Schleif, J.H. Nunberg, A.J. Conley, Y. Eda, S. Tokiyoshi, 
S.D. Putney, S. Matsushita, K.E. Cobb, C.M. Jett, et al. 1992. Prevention 
of HIV-1 infection in chimpanzees by gp120 V3 domain-specific mono-
clonal antibody. Nature. 355:728–730. doi:10.1038/355728a0
Freeze, H.H. 2001. Lectin Affinity Chromatography. Curr. Protoc. Protein 
Sci. Chapter 9: Unit 9.1.
Gauduin, M.C., J.T. Safrit, R. Weir, M.S. Fung, and R.A. Koup. 1995. 
Pre-  and  postexposure  protection  against  human  immunodeficiency   
virus type 1 infection mediated by a monoclonal antibody. J. Infect. Dis. 
171:1203–1209.
Karlsson  Hedestam,  G.B.,  R.A.  Fouchier,  S.  Phogat,  D.R.  Burton,  J. 
Sodroski, and R.T. Wyatt. 2008. The challenges of eliciting neutral-
izing antibodies to HIV-1 and to influenza virus. Nat. Rev. Microbiol. 
6:143–155. doi:10.1038/nrmicro1819
Korber, B.T., B.T. Foley, C.L. Kuiken, S.K. Pillai, and J.G. Sodroski. 1998. 
Numbering Positions in HIV Relative to HXB2CG. HIV Compendium. 
III:102–111.
Kwong, P.D., R. Wyatt, J. Robinson, R.W. Sweet, J. Sodroski, and W.A. 
Hendrickson. 1998. Structure of an HIV gp120 envelope glycoprotein 
in complex with the CD4 receptor and a neutralizing human antibody. 
Nature. 393:648–659. doi:10.1038/31405
Li, M., F. Gao, J.R. Mascola, L. Stamatatos, V.R. Polonis, M. Koutsoukos, G. 
Voss, P. Goepfert, P. Gilbert, K.M. Greene, et al. 2005. Human immuno-
deficiency virus type 1 env clones from acute and early subtype B infections 
for standardized assessments of vaccine-elicited neutralizing antibodies. 
J. Virol. 79:10108–10125. doi:10.1128/JVI.79.16.10108-10125.20052002 Characterization of the HIV-1 “core” epitope | Pietzsch et al.
memory B cells in HIV-infected individuals. Nature. 458:636–640. 
doi:10.1038/nature07930
Shibata, R., T. Igarashi, N. Haigwood, A. Buckler-White, R. Ogert, W. 
Ross, R. Willey, M.W. Cho, and M.A. Martin. 1999. Neutralizing an-
tibody directed against the HIV-1 envelope glycoprotein can completely 
block HIV-1/SIV chimeric virus infections of macaque monkeys. Nat. 
Med. 5:204–210. doi:10.1038/5568
Stamatatos, L., L. Morris, D.R. Burton, and J.R. Mascola. 2009. Neutralizing 
antibodies generated during natural HIV-1 infection: good news for an 
HIV-1 vaccine? Nat. Med. 15:866–870.
Thali,  M.,  U.  Olshevsky,  C.  Furman,  D.  Gabuzda,  M.  Posner,  and  J. 
Sodroski. 1991. Characterization of a discontinuous human immuno-
deficiency virus type 1 gp120 epitope recognized by a broadly reactive 
neutralizing human monoclonal antibody. J. Virol. 65:6188–6193.
Thali, M., J.P. Moore, C. Furman, M. Charles, D.D. Ho, J. Robinson, and 
J. Sodroski. 1993. Characterization of conserved human immunodefi-
ciency virus type 1 gp120 neutralization epitopes exposed upon gp120-
CD4 binding. J. Virol. 67:3978–3988.
Tiller, T., E. Meffre, S. Yurasov, M. Tsuiji, M.C. Nussenzweig, and H. 
Wardemann. 2008. Efficient generation of monoclonal antibodies from 
single human B cells by single cell RT-PCR and expression vector clon-
ing. J. Immunol. Methods. 329:112–124. doi:10.1016/j.jim.2007.09.017
Trkola, A., M. Purtscher, T. Muster, C. Ballaun, A. Buchacher, N. Sullivan, 
K. Srinivasan, J. Sodroski, J.P. Moore, and H. Katinger. 1996. Human 
monoclonal antibody 2G12 defines a distinctive neutralization epitope 
on the gp120 glycoprotein of human immunodeficiency virus type 1.   
J. Virol. 70:1100–1108.
Trkola, A., H. Kuster, P. Rusert, B. Joos, M. Fischer, C. Leemann, A. 
Manrique,  M.  Huber,  M.  Rehr,  A.  Oxenius,  et  al.  2005.  Delay   
of HIV-1 rebound after cessation of antiretroviral therapy through pas-
sive transfer of human neutralizing antibodies. Nat. Med. 11:615–622. 
doi:10.1038/nm1244
Walker, L.M., S.K. Phogat, P.Y. Chan-Hui, D. Wagner, P. Phung, J.L. 
Goss, T. Wrin, M.D. Simek, S. Fling, J.L. Mitcham, et al; Protocol G 
Principal Investigators. 2009. Broad and potent neutralizing antibodies 
from an African donor reveal a new HIV-1 vaccine target. Science. 326: 
285–289. doi:10.1126/science.1178746
Walker, L.M., and D.R. Burton. 2010. Rational antibody-based HIV-1 
vaccine design: current approaches and future directions. Curr. Opin. 
Immunol. 22:358–366.
Wardemann,  H.,  S.  Yurasov,  A.  Schaefer,  J.W.  Young,  E.  Meffre,  and 
M.C. Nussenzweig. 2003. Predominant autoantibody production by 
early  human  B  cell  precursors.  Science.  301:1374–1377.  doi:10.1126/ 
science.1086907.
Wyatt,  R.,  and  J.  Sodroski.  1998.  The  HIV-1  envelope  glycoproteins:   
fusogens, antigens, and immunogens. Science. 280:1884–1888. doi:10.1126/ 
science.280.5371.1884
Yang, X., J. Lee, E.M. Mahony, P.D. Kwong, R. Wyatt, and J. Sodroski. 
2002. Highly stable trimers formed by human immunodeficiency   
virus type 1 envelope glycoproteins fused with the trimeric motif of 
T4  bacteriophage  fibritin.  J.  Virol.  76:4634–4642.  doi:10.1128/JVI 
.76.9.4634-4642.2002
Zhou, T., L. Xu, B. Dey, A.J. Hessell, D. Van Ryk, S.H. Xiang, X. Yang, 
M.Y. Zhang, M.B. Zwick, J. Arthos, et al. 2007. Structural definition of 
a conserved neutralization epitope on HIV-1 gp120. Nature. 445:732–
737. doi:10.1038/nature05580
Zolla-Pazner, S. 2004. Identifying epitopes of HIV-1 that induce protective 
antibodies. Nat. Rev. Immunol. 4:199–210. doi:10.1038/nri1307